Seoul Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	52,149	53,580	52,459	50,057	40,463
Revenue	52,149	53,580	52,459	50,057	40,463
Revenue Growth (YoY)	-2.67%	2.14%	4.80%	23.71%	-22.53%
Cost of Revenue	20,646	20,651	20,871	17,910	14,980
Gross Profit	31,503	32,929	31,588	32,146	25,483
Selling, General & Admin	29,216	27,973	26,710	27,154	24,805
Research & Development	2,752	2,620	3,141	3,263	6,367
Amortization of Goodwill & Intangibles	27.99	31.79	37.07	-	-
Operating Expenses	32,782	31,401	30,375	30,408	31,197
Operating Income	-1,279	1,528	1,213	1,739	-5,713
Interest Expense	-577.3	-442.12	-442.51	-1,124	-1,132
Interest & Investment Income	229.41	301.9	383.64	325.22	122.1
Currency Exchange Gain (Loss)	4.46	256.31	15.32	72.17	87.73
Other Non Operating Income (Expenses)	2,256	49.15	2,819	45.18	-2,760
EBT Excluding Unusual Items	633.35	1,693	3,988	1,057	-9,396
Gain (Loss) on Sale of Investments	-	67.49	63.71	-	-
Gain (Loss) on Sale of Assets	-1.78	-0.05	-8.26	-0.02	2.19
Asset Writedown	-	-	-	-2,177	-198.8
Pretax Income	631.57	1,760	4,044	-1,120	-9,592
Income Tax Expense	-122.07	61.86	526.39	-1,975	96.14
Net Income	753.64	1,699	3,517	855.09	-9,689
Net Income to Common	753.64	1,699	3,517	855.09	-9,689
Net Income Growth	-55.63%	-51.71%	311.34%	-	-
Shares Outstanding (Basic)	-	12	12	9	9
Shares Outstanding (Diluted)	-	12	12	9	9
Shares Change (YoY)	-	-	29.84%	5.34%	0.31%
EPS (Basic)	-	145.69	301.68	95.23	-1136.55
EPS (Diluted)	-	145.69	301.68	95.23	-1136.55
EPS Growth	-	-51.71%	216.80%	-	-
Free Cash Flow	1,025	-5,237	3,372	-1,311	-2,831
Free Cash Flow Per Share	-	-449.20	289.20	-146.00	-332.16
Gross Margin	60.41%	61.46%	60.21%	64.22%	62.98%
Operating Margin	-2.45%	2.85%	2.31%	3.47%	-14.12%
Profit Margin	1.44%	3.17%	6.71%	1.71%	-23.95%
Free Cash Flow Margin	1.97%	-9.78%	6.43%	-2.62%	-7.00%
EBITDA	1,383	4,017	3,141	4,352	-3,185
EBITDA Margin	2.65%	7.50%	5.99%	8.69%	-7.87%
D&A For EBITDA	2,662	2,490	1,928	2,613	2,528
EBIT	-1,279	1,528	1,213	1,739	-5,713
EBIT Margin	-2.45%	2.85%	2.31%	3.47%	-14.12%
Effective Tax Rate	-	3.51%	13.02%	-	-
Advertising Expenses	90.06	244.7	282.26	340.07	306.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.